Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Rhea-AI Summary

Denali Therapeutics (Nasdaq: DNLI) will host a live webcast on Thursday, February 5, 2026 at 12:30 p.m. Pacific Time to review presentations on its Enzyme TransportVehicle™ (ETV) programs delivered at the 22nd Annual WORLDSymposium, held February 2–6, 2026 in San Diego.

The webcast will highlight the ETV approach to enable enzyme replacement therapy delivery across the whole body, including the brain, and is accessible via the Events page of Denali’s investor website.

Argus Feb 2 session

+4.60% close to close Open Argus

Details

News Market Reaction – DNLI

On Feb 2, the day this news came out, DNLI closed 4.60% above the previous close.

Data tracked by StockTitan Argus for the Feb 2 session.

Market Context

This announcement highlights a webcast focused on Denali’s Enzyme TransportVehicle™ programs at the ...

Analysis

This announcement highlights a webcast focused on Denali’s Enzyme TransportVehicle™ programs at the 22nd Annual WORLDSymposium™, adding visibility to its platform rather than introducing new data. The stock traded at $21.74, about 10.7% below its 52-week high and above the $15.61 200-day MA, reflecting prior momentum from milestones, funding, and regulatory progress. Investors may watch future clinical readouts, regulatory decisions, and any additional financing steps as more material catalysts beyond this communication event.

Key Figures

Conference dates: February 2–6, 2026 Webcast time: 12:30 p.m. Pacific Time Current price: $21.74 +5 more

Conference dates

February 2–6, 2026

22nd Annual WORLDSymposium schedule

Webcast time

12:30 p.m. Pacific Time

Start time on Thursday, February 5, 2026

Current price

$21.74

Pre-news trading level

24h price change

0.69%

Move prior to webcast announcement

52-week range

$10.57 – $24.345

Positioned 10.7% below 52-week high

Relative volume

1.54x

Today’s volume vs 20-day average

Market cap

$3,371,459,079

Equity value before webcast-focused news

200-day MA

$15.61

Price trading above long-term average

Historical Context

5 past events · Latest: Jan 06

5 events

1. Jan 06

   2026 milestones update

   24h Move

   +7.4%

   Outlined 2026 priorities, clinical readouts, and highlighted strong cash and financings.

2. Dec 30

   Clinical data NEJM

   24h Move

   -1.0%

   Published positive Phase 1/2 tividenofusp alfa data supporting FDA priority review.

3. Dec 10

   Public equity offering

   24h Move

   -10.6%

   Priced stock and pre-funded warrant offering targeting about $200M gross proceeds.

4. Dec 09

   Proposed equity offering

   24h Move

   -0.1%

   Announced proposed $200M stock and warrant sale with additional $30M option.

5. Dec 04

   Royalty funding deal

   24h Move

   +6.8%

   Entered $275M royalty funding agreement tied to future tividenofusp alfa sales.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

enzyme transportvehicle, enzyme replacement therapies

2 terms

enzyme transportvehicle medical

"presentations on its Enzyme TransportVehicle™ (ETV) programs at the upcoming"

An enzyme transportvehicle is a drug-delivery platform designed to carry large biologic medicines, such as enzymes or antibodies, across biological barriers (notably the blood–brain barrier) into target tissues. For investors, it matters because successful delivery technology can turn therapies that previously couldn’t reach key organs into viable drugs, expanding potential markets and creating licensing or partnership value much like a reliable shipping method turns hard-to-reach customers into reachable customers.

enzyme replacement therapies medical

"enable the delivery of enzyme replacement therapies to the whole body, including"

Enzyme replacement therapies are medical treatments that supply patients with missing or malfunctioning enzymes by administering lab-made versions, often through regular infusions. Like replacing a broken part in a machine to restore normal function, these therapies can transform chronic, debilitating conditions into manageable ones; for investors they matter because they often command high prices, face strict regulatory and manufacturing hurdles, and can drive predictable long-term revenue if widely adopted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme TransportVehicle™ (ETV) programs at the upcoming 22nd Annual WORLDSymposium™ being held February 2-6, 2026, in San Diego, California. These presentations will demonstrate the broad potential of the ETV to enable the delivery of enzyme replacement therapies to the whole body, including the brain. Titles and times for the presentations were previously announced in a corporate news release here. The live webcast will begin at 12:30 p.m. Pacific Time on Thursday, February 5, 2026, and can be accessed on the Events page of the Investor section on Denali’s corporate website at https://investors.denalitherapeutics.com/events or click here.

About Denali Therapeutics

Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle™ platform. With a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform the lives of people living with neurodegenerative, lysosomal storage and other serious diseases. For more information, please visit www.denalitherapeutics.com.

Investor Contact:
Laura Hansen, Ph.D.
hansen@dnli.com

Media Contact:
Erin Patton
epatton@dnli.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Denali Therapeutics (DNLI) hosting the ETV webcast for WORLDSymposium 2026?

The webcast will start on Thursday, February 5, 2026 at 12:30 p.m. Pacific Time. According to Denali Therapeutics, management will review presentations from the 22nd Annual WORLDSymposium held February 2–6, 2026 in San Diego.

How can investors access the DNLI webcast of ETV presentations on February 5, 2026?

Investors can access the live webcast via the Events page on Denali’s investor website. According to Denali Therapeutics, the webcast link is available on the investor Events page at https://investors.denalitherapeutics.com/events.

What topics will DNLI cover in the Enzyme TransportVehicle presentations at WORLDSymposium 2026?

Presentations will demonstrate the broad potential of the Enzyme TransportVehicle to deliver enzyme replacement therapies to the whole body, including the brain. According to Denali Therapeutics, the talks focus on ETV-enabled delivery across systemic and central nervous system tissues.

Which event are Denali’s ETV presentations associated with during February 2026?

Denali’s ETV presentations are part of the 22nd Annual WORLDSymposium taking place February 2–6, 2026 in San Diego. According to Denali Therapeutics, management will summarize those presentations via a live webcast on February 5, 2026.

Will the DNLI webcast review previously announced presentation titles and times from WORLDSymposium?

Yes, the webcast will review presentations whose titles and times were previously announced. According to Denali Therapeutics, the specific presentation schedule had been released in an earlier corporate notice.